Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Noble Corp.: July Fleet Status Report Analysis

3h seekingalpha
Noble Corp. (NE) has recently provided its July fleet status report. There were major changes compared to the June fleet status report which contained no news at all, so let's look closely at the latest developments.
NE NOBGF N21 NOBGY

2
Veeva Systems' Development Cloud Platform Picked by Idorsia

2018-07-17 zacks
Shares of Veeva Systems (VEEV - Free Report) climbed 3.5% to $82.23 following the company’s recent collaboration with Idorsia Pharmaceuticals Ltd.
RCIAF NOBGF RCI N21 SYK VEEV NOBGY GHDX SGH

10
Americans on a Spring Spending Spree: Top 5 Gainers

2018-07-17 zacks
Headline retail sales rose for the fifth successive month in June, with health & personal care stores, building materials and even online shopping seeing an uptick in sales. Sales at bars and restaurants surged during late spring to the highest level in about three years.
GRPN RCIAF NOBGF RCI N21 NOBGY DRI CVS SGH TAST

3
Noble Corp (NE) Wins 2 New Contracts, Extension

2018-07-16 zacks
Noble Corporation plc (NE - Free Report) recently published its fleet status report, per which the company has won two new contracts as well as received an extension for one of its jackup rigs.
ECA NOC ECN NE NOBGF XOM N21 NOBGY ECA

15
Amazon as a Value Stock? Believe It - Bloomberg

2018-07-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
IBM NOBGF UPS BC94 WBA SMSN NFLX CVS N21 OCLCF NOBGY ORCL SMSD

0
Cypriot-American CEO of Barnes & Noble Demos Parneros Fired

2018-07-03 thenationalherald
Demos Parneros, who had acted as chief operating officer, was Barnes & Noble’s fourth chief executive since 2013. Photo: Barnes & Noble website
NOBGF N21 NOBGY

0
Barnes & Noble boots out CEO for policy violations

2018-07-03 malaymail
NEW YORK, July 4 — Barnes & Noble Inc said yesterday it terminated Demos Parneros as chief executive officer, citing violations of the bookseller's policies.
NOBGF N21 NOBGY

0
Barnes & Noble terminates CEO for company policy violations

2018-07-03 nzherald.co.nz
NEW YORK (AP) — Barnes & Noble Inc. is terminating CEO Demos Parneros after barely a year on the job for violating company policies.
NOBGF N21 NOBGY

0
Barnes & Noble boots out CEO for policy violations

2018-07-03 channelnewsasia
Barnes & Noble Inc on Tuesday said it terminated Chief Executive Officer Demos Parneros, citing violations of the retail bookseller's policies.
NOBGF N21 NOBGY

0
Barnes & Noble terminates CEO Demos Parneros

2018-07-03 reuters
(Reuters) - Barnes & Noble Inc (BKS.N) on Tuesday said it terminated Chief Executive Officer Demos Parneros, citing violations of the retail bookseller’s policies.
NOBGF N21 NOBGY

0
Barnes & Noble terminates CEO Demos Parneros

2018-07-03 channelnewsasia
Barnes & Noble Inc on Tuesday said it terminated Chief Executive Officer Demos Parneros, citing violations of the retail bookseller's policies.
NOBGF N21 NOBGY

0
Barnes & Noble terminates CEO, says he violated company policies - MarketWatch

2018-07-03 marketwatch
Barnes & Noble Inc. BKS, -4.00% announced the termination of its chief executive Tuesday afternoon, saying that he had committed "violations of the company's policies." The bookstore chain did not go into more detail on why its board had decided to fire Demos Parneros, only explaining it had been advised by an outside law firm on the decision. A trio of top executives -- CFO Allen Lindstrom, CMO Tim Mantel and Carl Hauch -- will share CEO duties in the interim, with assistance from Executive Chairman Leonard Riggio.
NOBGF N21 NOBGY

2
BKS Stock Price - Barnes & Noble Inc. Stock Quote (U.S.: NYSE) - MarketWatch

2018-07-03 marketwatch
Barnes & Noble Inc. shares fell 3.1% in Thursday premarket trading after the bookseller reported wider fiscal fourth-quarter losses. Net loss for the quarter was $21.1 million, or 29 cents per share, greater than the loss of $13.4 million, or 19 cents per share, for the same period last year. The loss includes $7.7 million in non-recurring charges. Revenue totaled $786.1 million, down from $821.2 million last year.
EQM MDURN NOBGF MDURI N21 MOH NOBGY MDURP BEAV MDU

23
Yancoal to dual list onto Hong Kong exchange

2018-07-02 theage.com.au
Coal miner Yancoal will list on the Hong Kong exchange before the end of 2018 to open its books beyond five shareholders and see movement in its share price.
YZC RTPPF K3GD RIO NOBGF RIO 1171 YZCHF N21 RIO NOBGY RTNTF

23
Yancoal to dual list onto Hong Kong exchange

2018-07-02 smh.com.au
Coal miner Yancoal will list on the Hong Kong exchange before the end of 2018 to open its books beyond five shareholders and see movement in its share price.
YZC RTPPF K3GD RIO NOBGF RIO 1171 YZCHF N21 RIO NOBGY RTNTF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 65504R104